Effect of Topical 5% 5-Fluorouracil with Microneedling in Vitiligo Patients as an Additional Modality to Standard Treatment at Tertiary Care Hospital.

IF 1.9 Q3 DERMATOLOGY Indian Dermatology Online Journal Pub Date : 2024-04-29 eCollection Date: 2024-05-01 DOI:10.4103/idoj.idoj_774_23
Valay A Desai, Anjum M Momin, Jignesh B Vaishnani
{"title":"Effect of Topical 5% 5-Fluorouracil with Microneedling in Vitiligo Patients as an Additional Modality to Standard Treatment at Tertiary Care Hospital.","authors":"Valay A Desai, Anjum M Momin, Jignesh B Vaishnani","doi":"10.4103/idoj.idoj_774_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vitiligo is an inveterate disease of great aesthetic concern presenting with depigmented macules and patches. It is often incorrigible to medical treatment.</p><p><strong>Aim: </strong>To study the clinical profile of vitiligo patients and evaluate the effect of 5% 5-fluorouracil (5-FU) cream with microneedling.</p><p><strong>Materials and methods: </strong>This observational analytical study was conducted from November 2019 to July 2021. A total of 33 adult vitiligo patients were treated with oral mini-pulse (dexamethasone) therapy and topical corticosteroid (clobetasol propionate 0.05%). Patient's total number of vitiligo lesions with <10-cm size were counted and half of the lesions were treated with 5-FU + microneedling (Group A), while a remaining number of lesions were not treated with 5-FU + microneedling (Group B). In the case of the odd number of lesions, the total number of lesions minus one was considered and then divided into equal numbers for treatment. The procedure was performed every 2 weeks for 3 months. Clinical improvement was assessed monthly till 6 months by serial clinical photographs and grading scores.</p><p><strong>Results: </strong>Initiation of repigmentation started in the first month in Group A, whereas in Group B, it was seen in the second, which was statistically significant (<i>P</i> < 0.0001). Excellent improvement (>75% repigmentation) was noted in Group A as compared to Group B at the end of 6 months (<i>P</i> < 0.0001).</p><p><strong>Conclusions: </strong>Needling with 5% 5-FU appears to be a simple, safe, and effective treatment in vitiligo. It can be used in poor responders to conventional therapy.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 3","pages":"443-448"},"PeriodicalIF":1.9000,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152467/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Dermatology Online Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/idoj.idoj_774_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Vitiligo is an inveterate disease of great aesthetic concern presenting with depigmented macules and patches. It is often incorrigible to medical treatment.

Aim: To study the clinical profile of vitiligo patients and evaluate the effect of 5% 5-fluorouracil (5-FU) cream with microneedling.

Materials and methods: This observational analytical study was conducted from November 2019 to July 2021. A total of 33 adult vitiligo patients were treated with oral mini-pulse (dexamethasone) therapy and topical corticosteroid (clobetasol propionate 0.05%). Patient's total number of vitiligo lesions with <10-cm size were counted and half of the lesions were treated with 5-FU + microneedling (Group A), while a remaining number of lesions were not treated with 5-FU + microneedling (Group B). In the case of the odd number of lesions, the total number of lesions minus one was considered and then divided into equal numbers for treatment. The procedure was performed every 2 weeks for 3 months. Clinical improvement was assessed monthly till 6 months by serial clinical photographs and grading scores.

Results: Initiation of repigmentation started in the first month in Group A, whereas in Group B, it was seen in the second, which was statistically significant (P < 0.0001). Excellent improvement (>75% repigmentation) was noted in Group A as compared to Group B at the end of 6 months (P < 0.0001).

Conclusions: Needling with 5% 5-FU appears to be a simple, safe, and effective treatment in vitiligo. It can be used in poor responders to conventional therapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
5% 5-氟尿嘧啶外用药与微针疗法在白癜风患者中的应用效果,作为三甲医院标准治疗的补充方法。
背景:白癜风是一种严重影响美观的顽固性疾病,表现为脱色斑和斑块。目的:研究白癜风患者的临床概况,并评估 5%5-氟尿嘧啶(5-FU)乳膏与微针疗法的效果:本观察分析研究于2019年11月至2021年7月进行。共有33名成年白癜风患者接受了口服小脉冲(地塞米松)疗法和外用皮质类固醇激素(丙酸氯倍他索0.05%)治疗。患者的白癜风皮损总数与结果:A 组在第一个月就开始出现色素沉着,而 B 组在第二个月就开始出现色素沉着,这在统计学上有显著意义(P < 0.0001)。与 B 组相比,A 组在 6 个月后的色素沉着明显改善(>75%)(P < 0.0001):结论:使用5% 5-FU进行针刺似乎是一种简单、安全、有效的白癜风治疗方法。结论:使用5% 5-FU进行针刺治疗似乎是一种简单、安全且有效的白癜风治疗方法,可用于对传统疗法反应不佳的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.00
自引率
11.80%
发文量
201
审稿时长
49 weeks
期刊最新文献
Bicalutamide in Dermatology: A Narrative Review. Clinicopathological Profile of Pyoderma Gangrenosum: A 10-Year Retrospective Study from a Tertiary Care Center in South India. Novel Inflammatory Markers Associated With Cutaneous Leukocytoclastic Vasculitis Etiology. Pediatric Basidiobolomycosis: An Uncommon and Misdiagnosed Entity. Premature Graying of Hair: A Comprehensive Review and Recent Insights.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1